Skip to main content
main-content
Erschienen in: Geriatrie-Report 3/2019

15.08.2019 | Der geriatrische Patient in der Hausarztpraxis | Zertifizierte Fortbildung

Wenn die Knochen brüchig werden

Osteoporose: Oberstes Ziel ist die Vermeidung von Frakturen

verfasst von: MA Dr. Franca Genest, Dr. Lothar Seefried

Erschienen in: Geriatrie-Report | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Vitamin-D-Mangel, Medikamente, Multimorbidität — im Alter häufen sich die Risikofaktoren für osteoporotische Knochenbrüche. Insbesondere für ältere Menschen sind Frakturen ein einschneidendes Erlebnis, dass nicht selten zu Immobilität oder Pflegebedürftigkeit führt. Um ein erhöhtes Risiko frühzeitig zu erkennen und adäquat reagieren zu können, sollte der Hausarzt die richtigen Fragen stellen und die Warnzeichen für drohende Knochenbrüche kennen.
Literatur
1.
Zurück zum Zitat Jakob F, Seefried L, Schwab M. [Age and osteoporosis. Effects of aging on osteoporosis, the diagnostics and therapy]. Der Internist. 2014;55(7):755–61. PubMedCrossRef Jakob F, Seefried L, Schwab M. [Age and osteoporosis. Effects of aging on osteoporosis, the diagnostics and therapy]. Der Internist. 2014;55(7):755–61. PubMedCrossRef
2.
Zurück zum Zitat Van Der Klift M, Pols HA, Geleijnse JM, Van Der Kuip DA, Hofman A, De Laet CE. Bone mineral density and mortality in elderly men and women: the Rotterdam Study. Bone. 2002;30(4):643–8. PubMedCrossRef Van Der Klift M, Pols HA, Geleijnse JM, Van Der Kuip DA, Hofman A, De Laet CE. Bone mineral density and mortality in elderly men and women: the Rotterdam Study. Bone. 2002;30(4):643–8. PubMedCrossRef
3.
Zurück zum Zitat Hadji P, Klein S, Gothe H, Haussler B, Kless T, Schmidt T, et al. The epidemiology of osteoporosis—Bone Evaluation Study (BEST): an analysis of routine health insurance data. Deutsches Arzteblatt international. 2013;110(4):52–7 PubMedPubMedCentral Hadji P, Klein S, Gothe H, Haussler B, Kless T, Schmidt T, et al. The epidemiology of osteoporosis—Bone Evaluation Study (BEST): an analysis of routine health insurance data. Deutsches Arzteblatt international. 2013;110(4):52–7 PubMedPubMedCentral
4.
Zurück zum Zitat Jakob F, Seefried L, Ebert R. [Pathophysiology of bone metabolism]. Der Internist. 2008;49(10):1159–60, 62, 64 passim. PubMedCrossRef Jakob F, Seefried L, Ebert R. [Pathophysiology of bone metabolism]. Der Internist. 2008;49(10):1159–60, 62, 64 passim. PubMedCrossRef
5.
Zurück zum Zitat Bar-Shavit Z. The osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell. Journal of cellular biochemistry. 2007;102(5):1130–9. PubMedCrossRef Bar-Shavit Z. The osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell. Journal of cellular biochemistry. 2007;102(5):1130–9. PubMedCrossRef
6.
Zurück zum Zitat Novack DV, Teitelbaum SL. The osteoclast: friend or foe? Annu Rev Pathol. 2008;3:457–84. CrossRef Novack DV, Teitelbaum SL. The osteoclast: friend or foe? Annu Rev Pathol. 2008;3:457–84. CrossRef
8.
Zurück zum Zitat Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int. 2004;15(3):175–9. PubMedCrossRef Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int. 2004;15(3):175–9. PubMedCrossRef
9.
Zurück zum Zitat Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375–82. PubMedCrossRef Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375–82. PubMedCrossRef
10.
Zurück zum Zitat Lunt M, O’Neill TW, Felsenberg D, Reeve J, Kanis JA, Cooper C, et al. Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). Bone. 2003;33(4):505–13. PubMedCrossRef Lunt M, O’Neill TW, Felsenberg D, Reeve J, Kanis JA, Cooper C, et al. Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). Bone. 2003;33(4):505–13. PubMedCrossRef
11.
Zurück zum Zitat Eklund F, Nordstrom A, Bjornstig U, Nordstrom P. Bone mass, size and previous fractures as predictors of prospective fractures in an osteoporotic referral population. Bone. 2009;45(4):808–13. PubMedCrossRef Eklund F, Nordstrom A, Bjornstig U, Nordstrom P. Bone mass, size and previous fractures as predictors of prospective fractures in an osteoporotic referral population. Bone. 2009;45(4):808–13. PubMedCrossRef
12.
Zurück zum Zitat Franca Genest LS. Süße Knochen brechen leichter. Der Allgemeinarzt 2018;40 (17) Seite 34–8. Franca Genest LS. Süße Knochen brechen leichter. Der Allgemeinarzt 2018;40 (17) Seite 34–8.
13.
Zurück zum Zitat Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nature reviews Endocrinology. 2017;13(4):208–19. PubMedCrossRef Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nature reviews Endocrinology. 2017;13(4):208–19. PubMedCrossRef
14.
Zurück zum Zitat Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91(9):3404–10. PubMedCrossRef Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91(9):3404–10. PubMedCrossRef
15.
Zurück zum Zitat Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 2012;27(5):319–32. PubMedPubMedCentralCrossRef Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 2012;27(5):319–32. PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Farr JN, Zhang W, Kumar SK, Jacques RM, Ng AC, McCready LK, et al. Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. Blood. 2014;123(5):647–9. PubMedPubMedCentralCrossRef Farr JN, Zhang W, Kumar SK, Jacques RM, Ng AC, McCready LK, et al. Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. Blood. 2014;123(5):647–9. PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Drake MT. unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance? J Bone Miner Res. 2014;29(12):2529–33. PubMedPubMedCentralCrossRef Drake MT. unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance? J Bone Miner Res. 2014;29(12):2529–33. PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Seppala LJ, van der Velde N, Masud T, Blain H, Petrovic M, van der Cammen TJ, et al. EuGMS Task and Finish group on Fall-Risk-Increasing Drugs (FRIDs): Position on Knowledge Dissemination, Management, and Future Research. Drugs Aging. 2019;36(4):299–307. PubMedPubMedCentralCrossRef Seppala LJ, van der Velde N, Masud T, Blain H, Petrovic M, van der Cammen TJ, et al. EuGMS Task and Finish group on Fall-Risk-Increasing Drugs (FRIDs): Position on Knowledge Dissemination, Management, and Future Research. Drugs Aging. 2019;36(4):299–307. PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Picca A, Calvani R, Manes-Gravina E, Spaziani L, Landi F, Bernabei R, et al. Bone-Muscle Crosstalk: Unraveling New Therapeutic Targets for Osteoporosis. Current pharmaceutical design. 2017;23(41):6256–63. PubMedCrossRef Picca A, Calvani R, Manes-Gravina E, Spaziani L, Landi F, Bernabei R, et al. Bone-Muscle Crosstalk: Unraveling New Therapeutic Targets for Osteoporosis. Current pharmaceutical design. 2017;23(41):6256–63. PubMedCrossRef
20.
Zurück zum Zitat Wagner P, Chapurlat R, Ecochard R, Szulc P. Low Muscle Strength and Mass Is Associated With the Accelerated Decline of Bone Microarchitecture at the Distal Radius in Older Men: the Prospective STRAMBO Study. J Bone Miner Res. 2018;33(9):1630–40. PubMedCrossRef Wagner P, Chapurlat R, Ecochard R, Szulc P. Low Muscle Strength and Mass Is Associated With the Accelerated Decline of Bone Microarchitecture at the Distal Radius in Older Men: the Prospective STRAMBO Study. J Bone Miner Res. 2018;33(9):1630–40. PubMedCrossRef
21.
Zurück zum Zitat Jain RK, Vokes T. Dual-energy X-ray Absorptiometry. Journal of clinical densitometry: the official journal of the International Society for Clinical Densitometry. 2017;20(3):291–303. CrossRef Jain RK, Vokes T. Dual-energy X-ray Absorptiometry. Journal of clinical densitometry: the official journal of the International Society for Clinical Densitometry. 2017;20(3):291–303. CrossRef
22.
Zurück zum Zitat Lewiecki EM. Bone densitometry and vertebral fracture assessment. Current osteoporosis reports. 2010;8(3):123–30. PubMedCrossRef Lewiecki EM. Bone densitometry and vertebral fracture assessment. Current osteoporosis reports. 2010;8(3):123–30. PubMedCrossRef
23.
Zurück zum Zitat Flicker L, Mead K, MacInnis RJ, Nowson C, Scherer S, Stein MS, et al. Serum vitamin D and falls in older women in residential care in Australia. J Am Geriatr Soc. 2003;51(11):1533–8. PubMedCrossRef Flicker L, Mead K, MacInnis RJ, Nowson C, Scherer S, Stein MS, et al. Serum vitamin D and falls in older women in residential care in Australia. J Am Geriatr Soc. 2003;51(11):1533–8. PubMedCrossRef
24.
Zurück zum Zitat Garnero P, Munoz F, Sornay-Rendu E, Delmas PD. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone. 2007;40(3):716–22. PubMedCrossRef Garnero P, Munoz F, Sornay-Rendu E, Delmas PD. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone. 2007;40(3):716–22. PubMedCrossRef
25.
Zurück zum Zitat Sambrook PN, Chen JS, March LM, Cameron ID, Cumming RG, Lord SR, et al. Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin d status, bone mass, and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab. 2004;89(11):5477–81. PubMedCrossRef Sambrook PN, Chen JS, March LM, Cameron ID, Cumming RG, Lord SR, et al. Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin d status, bone mass, and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab. 2004;89(11):5477–81. PubMedCrossRef
26.
Zurück zum Zitat Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int. 2009;20(2):315–22. PubMedCrossRef Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int. 2009;20(2):315–22. PubMedCrossRef
27.
Zurück zum Zitat Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res. 2004;19(3):370–8. PubMedCrossRef Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res. 2004;19(3):370–8. PubMedCrossRef
28.
Zurück zum Zitat Saita Y, Ishijima M, Kaneko K. Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications. Therapeutic advances in chronic disease. 2015;6(4):185–93. PubMedPubMedCentralCrossRef Saita Y, Ishijima M, Kaneko K. Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications. Therapeutic advances in chronic disease. 2015;6(4):185–93. PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94. PubMedCrossRef Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94. PubMedCrossRef
30.
Zurück zum Zitat Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23. PubMedCrossRef Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23. PubMedCrossRef
31.
Zurück zum Zitat Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–23. PubMedCrossRef Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–23. PubMedCrossRef
32.
Zurück zum Zitat Watts NB, Brown JP, Papapoulos S, Lewiecki EM, Kendler DL, Dakin P, et al. Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension. J Bone Miner Res. 2017;32(7):1481–5. PubMedCrossRef Watts NB, Brown JP, Papapoulos S, Lewiecki EM, Kendler DL, Dakin P, et al. Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension. J Bone Miner Res. 2017;32(7):1481–5. PubMedCrossRef
33.
Zurück zum Zitat Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65. PubMedCrossRef Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65. PubMedCrossRef
34.
Zurück zum Zitat Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N, et al. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017;105:11–7. PubMedCrossRef Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N, et al. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017;105:11–7. PubMedCrossRef
36.
Zurück zum Zitat Leder BZ, Tsai JN, Jiang LA, Lee H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Bone. 2017;98:54–8. PubMedCrossRef Leder BZ, Tsai JN, Jiang LA, Lee H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Bone. 2017;98:54–8. PubMedCrossRef
37.
Zurück zum Zitat Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, et al. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. J Bone Miner Res. 2019;34(3):419–28. PubMedCrossRef Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, et al. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. J Bone Miner Res. 2019;34(3):419–28. PubMedCrossRef
39.
Zurück zum Zitat Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, et al. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183–93. PubMedCrossRef Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, et al. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183–93. PubMedCrossRef
40.
Zurück zum Zitat Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016;375(16):1532–43. PubMedCrossRef Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016;375(16):1532–43. PubMedCrossRef
Metadaten
Titel
Wenn die Knochen brüchig werden
Osteoporose: Oberstes Ziel ist die Vermeidung von Frakturen
verfasst von
MA Dr. Franca Genest
Dr. Lothar Seefried
Publikationsdatum
15.08.2019
Verlag
Springer Medizin
Erschienen in
Geriatrie-Report / Ausgabe 3/2019
Print ISSN: 1862-5363
Elektronische ISSN: 2520-8950
DOI
https://doi.org/10.1007/s42090-019-0179-6